Pancreatic adenocarcinoma advanced or metastatic
Clinical trials for Pancreatic adenocarcinoma advanced or metastatic explained in plain language.
Never miss a new study
Get alerted when new Pancreatic adenocarcinoma advanced or metastatic trials appear
Sign up with your email to follow new studies for Pancreatic adenocarcinoma advanced or metastatic, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can switching chemo cocktails extend lives in pancreatic cancer?
Disease control Recruiting nowResearchers are comparing two chemotherapy approaches for people with advanced pancreatic cancer that has not worsened after three months of initial treatment with mFOLFIRINOX. One group continues mFOLFIRINOX, while the other switches to gemcitabine plus nab-paclitaxel. The trial…
Matched conditions: PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC
Phase 3 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug CT-95 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…
Matched conditions: PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC
Phase 1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug INV-8989 targets Hard-to-Treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …
Matched conditions: PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC
Phase 1/2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC